Phase I trial of fixed dose rate infusion (FDRI) gemcitabine (GEM) with gefitinib in patients with advanced pancreatic carcinoma.

被引：0
|
作者：
Carneiro, B [1 ]
Brand, R [1 ]
Fine, E [1 ]
Knop, R [1 ]
Khandekar, J [1 ]
Uhlig, W [1 ]
Locker, GY [1 ]
机构：
[1] Evanston NW Healthcare, Evanston, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：337S / 337S
页数：1
相关论文
共 50 条
  • [31] A phase I trial of weekly gemcitabine (GEM), administered as a constant dose-rate infusion, and docetaxel (DOC) in patients with advanced solid tumors (LOA-8).
    Rinaldi, DA
    Lormand, NA
    Rainey, JM
    Brierre, JE
    Cole, JL
    Roden, KB
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 149S - 149S
  • [32] Phase I Trial of Fixed-Dose Rate Gemcitabine in Combination with Bortezomib in Advanced Solid Tumors
    Luu, Thehang
    Chow, Warren
    Lim, Dean
    Koczywas, Marianna
    Frankel, Paul
    Cristea, Mihaela
    Margolin, Kim
    Doroshow, James H.
    Somlo, George
    Gaur, Shikha
    Yen, Yun
    Morgan, Robert J.
    ANTICANCER RESEARCH, 2010, 30 (01) : 167 - 174
  • [33] Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: A phase II study
    Kim, Hawk
    Park, Jae-Hoo
    Shin, Su Jin
    Kim, Mee-Ja
    Bang, Sung-Jo
    Park, Neung Hwa
    Nah, Yang Won
    Nam, Chang Woo
    Joo, Kwang Ro
    Min, Young Joo
    CHEMOTHERAPY, 2008, 54 (01) : 54 - 62
  • [34] Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine plus oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201)
    Poplin, E.
    Levy, D. E.
    Berlin, J.
    Rothenberg, M. L.
    O'Dwyer, P. J.
    Cella, D.
    Mitchell, E.
    Alberts, S.
    Benson, A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 933S - 933S
  • [35] A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer
    Sun, Weijing
    Hewitt, Maureen R.
    Theobald, Marry R.
    Hershock, Diane
    Haller, Daniel G.
    CANCER, 2007, 110 (12) : 2768 - 2774
  • [36] A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients
    Santini, D.
    Virzi, V.
    Vincenzi, B.
    Rocci, L.
    Leoni, V.
    Tonini, G.
    ANNALS OF ONCOLOGY, 2007, 18 (03) : 576 - 580
  • [37] Fixed dose-rate gemcitabine (FDR-Gem) infusion as first-line treatment for advanced pancreatic and biliary tree cancer
    Gelibter, Alain
    Malaguti, Paola
    Di Cosimo, Serena
    Bria, Emilio
    Ruggeri, Enzo Maria
    Carlini, Paolo
    Sperduti, Isabella
    Giannarelli, Diana
    Terzoli, Edmondo
    Cognetti, Francesco
    Milella, Michele
    ANNALS OF ONCOLOGY, 2005, 16 : 53 - 54
  • [38] A phase I/II study of gemcitabine (GEM) with oral S-1 in metastatic pancreatic carcinoma.
    Nakamura, K
    Yamaguchi, T
    Ishihara, T
    Ishiguro, H
    Kabayashi, A
    Tadenuma, H
    Saisyo, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 346S - 346S
  • [39] Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas
    J. Feliu
    J. García Sáenz
    A. Rodríguez Jaráiz
    C. Castañón
    M. Cruz
    E. Fonseca
    M. Lomas
    J. Castro
    C. Jara
    E. Casado
    A. León
    M. González Barón
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 419 - 426
  • [40] Phase I dose-escalating study of bi-weekly pemetrexed (MTA) with fixed dose rate gemcitabine (gem) in patients with advanced cancer.
    Chen, A. L.
    Ryan, T.
    Muggia, F.
    Chachoua, A.
    Escalon, J.
    Moore, S.
    Haniff, F.
    Levinson, B.
    Nicol, S.
    Hochster, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 91S - 91S
12345